Cinaciguat

Cinaciguat
Clinical data
Routes of
administration		intravenous (?)
ATC code
  • none
Identifiers
IUPAC name
  • 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)
    phenyl]methoxy}phenyl)ethyl]amino}methyl)
    benzoic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC36H39NO5
Molar mass565.710 g·mol−1
3D model (JSmol)
SMILES
  • c4ccccc4CCc3ccc(cc3)COc1ccccc1CCN(CCCCC(O)=O)Cc2ccc(C(=O)O)cc2
InChI
  • InChI=1S/C36H39NO5/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41) ☒N
  • Key:WPYWMXNXEZFMAK-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Mechanism of action

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]

See also

  • Riociguat, another drug stimulating sGC, but with a different mechanism
  • PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.

References

  1. ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.